Your browser doesn't support javascript.
loading
Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13).
Novak, Urban; Fehr, Martin; Schär, Sämi; Dreyling, Martin; Schmidt, Christian; Derenzini, Enrico; Zander, Thilo; Hess, Georg; Mey, Ulrich; Ferrero, Simone; Mach, Nicolas; Boccomini, Carola; Böttcher, Sebastian; Voegeli, Michèle; Cairoli, Anne; Ivanova, Vanesa-Sindi; Menter, Thomas; Dirnhofer, Stefan; Scheibe, Bernhard; Gadient, Sandra; Eckhardt, Katrin; Zucca, Emanuele; Driessen, Christoph; Renner, Christoph.
Affiliation
  • Novak U; Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Switzerland.
  • Fehr M; Department of Medical Oncology and Haematology, Kantonsspital Sankt Gallen, Switzerland.
  • Schär S; SAKK Competence Centre, Bern, Switzerland.
  • Dreyling M; Department of Medicine III, University Hospital, Ludwig Maximilian University, Munich, Germany.
  • Schmidt C; Department of Medicine III, University Hospital, Ludwig Maximilian University, Munich, Germany.
  • Derenzini E; Onco-Haematology Division, IEO European Institute of Oncology IRCCS, Department of Health Sciences, University of Milan, Italy.
  • Zander T; Division of Medical Oncology, Luzerner Kantonsspital, Switzerland.
  • Hess G; University Medical Centre of the Johannes Gutenberg University Mainz, Germany.
  • Mey U; Department of Oncology and Haematology, Kantonsspital Graubünden, Switzerland.
  • Ferrero S; Haematology Department of Molecular Biotechnologies and Health Sciences, University of Torino, and Haematology 1, AOU "Città della Salute e della Scienza di Torino", Italy.
  • Mach N; Department of Oncology, University Hospital of Geneva, Switzerland.
  • Boccomini C; AOU "Città della Salute e della Scienza di Torino", Italy.
  • Böttcher S; Department of Medicine, Clinic III, Rostock University Medical Centre, Germany.
  • Voegeli M; Department of Haematology and Oncology, Kantonsspital Baselland, Liestal, Switzerland.
  • Cairoli A; Department of Oncology, Lausanne University Hospital and University of Lausanne, Switzerland.
  • Ivanova VS; Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Switzerland.
  • Menter T; Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Switzerland.
  • Dirnhofer S; Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Switzerland.
  • Scheibe B; SAKK Competence Centre, Bern, Switzerland.
  • Gadient S; SAKK Competence Centre, Bern, Switzerland.
  • Eckhardt K; SAKK Competence Centre, Bern, Switzerland.
  • Zucca E; Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona, Switzerland.
  • Driessen C; Department of Medical Oncology and Haematology, Kantonsspital Sankt Gallen, Switzerland.
  • Renner C; Onkozentrum Hirslanden & Zürich, Switzerland.
EClinicalMedicine ; 64: 102221, 2023 Oct.
Article de En | MEDLINE | ID: mdl-37781158
Mots clés
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Type d'étude: Etiology_studies / Risk_factors_studies Langue: En Journal: EClinicalMedicine Année: 2023 Type de document: Article Pays d'affiliation: Suisse Pays de publication: Royaume-Uni
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Type d'étude: Etiology_studies / Risk_factors_studies Langue: En Journal: EClinicalMedicine Année: 2023 Type de document: Article Pays d'affiliation: Suisse Pays de publication: Royaume-Uni